IL138027A - Intermediates for the preparation and preparation of metalloproteinase inhibitors - Google Patents

Intermediates for the preparation and preparation of metalloproteinase inhibitors

Info

Publication number
IL138027A
IL138027A IL13802796A IL13802796A IL138027A IL 138027 A IL138027 A IL 138027A IL 13802796 A IL13802796 A IL 13802796A IL 13802796 A IL13802796 A IL 13802796A IL 138027 A IL138027 A IL 138027A
Authority
IL
Israel
Prior art keywords
group
formula
salt
compound
heterocycloalkyl
Prior art date
Application number
IL13802796A
Other languages
English (en)
Hebrew (he)
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of IL138027A publication Critical patent/IL138027A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13802796A 1995-12-08 1996-12-05 Intermediates for the preparation and preparation of metalloproteinase inhibitors IL138027A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56976695A 1995-12-08 1995-12-08
IL12455996A IL124559A (en) 1995-12-08 1996-12-05 Inhibitors of metalloproteinases, pharmaceutical preparations containing them and their use

Publications (1)

Publication Number Publication Date
IL138027A true IL138027A (en) 2004-08-31

Family

ID=24276764

Family Applications (6)

Application Number Title Priority Date Filing Date
IL13802796A IL138027A (en) 1995-12-08 1996-12-05 Intermediates for the preparation and preparation of metalloproteinase inhibitors
IL13481696A IL134816A (en) 1995-12-08 1996-12-05 Substituted diarylether sulfonic acids and their preparation
IL12455996A IL124559A (en) 1995-12-08 1996-12-05 Inhibitors of metalloproteinases, pharmaceutical preparations containing them and their use
IL13802700A IL138027A0 (en) 1995-12-08 2000-08-23 Intermediates of metalloproteinase inhibitors and a method for their preparation
IL13802800A IL138028A0 (en) 1995-12-08 2000-08-23 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
IL14367401A IL143674A0 (en) 1995-12-08 2001-06-11 Metalloproteinase inhibitors, and the methods for making these

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL13481696A IL134816A (en) 1995-12-08 1996-12-05 Substituted diarylether sulfonic acids and their preparation
IL12455996A IL124559A (en) 1995-12-08 1996-12-05 Inhibitors of metalloproteinases, pharmaceutical preparations containing them and their use
IL13802700A IL138027A0 (en) 1995-12-08 2000-08-23 Intermediates of metalloproteinase inhibitors and a method for their preparation
IL13802800A IL138028A0 (en) 1995-12-08 2000-08-23 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
IL14367401A IL143674A0 (en) 1995-12-08 2001-06-11 Metalloproteinase inhibitors, and the methods for making these

Country Status (39)

Country Link
US (1) US6153757A (de)
EP (2) EP0874830B1 (de)
JP (1) JP2000502330A (de)
KR (1) KR19990072009A (de)
CN (2) CN1542002A (de)
AP (2) AP1368A (de)
AT (2) ATE234291T1 (de)
AU (1) AU725831C (de)
BG (1) BG64279B1 (de)
BR (1) BR9611929A (de)
CA (1) CA2238306A1 (de)
CO (1) CO4790150A1 (de)
CZ (1) CZ292942B6 (de)
DE (2) DE69626684T2 (de)
DK (1) DK0874830T3 (de)
EA (1) EA003294B1 (de)
ES (2) ES2233275T3 (de)
GE (1) GEP20012388B (de)
GT (2) GT199700015AA (de)
HR (1) HRP970031A2 (de)
HU (1) HUP9902092A3 (de)
ID (1) ID17624A (de)
IL (6) IL138027A (de)
MX (1) MX9804457A (de)
MY (1) MY117290A (de)
NO (1) NO311360B1 (de)
NZ (1) NZ325559A (de)
OA (1) OA10794A (de)
PA (1) PA8431301A1 (de)
PE (1) PE69298A1 (de)
PL (1) PL327275A1 (de)
PT (1) PT874830E (de)
SI (1) SI0874830T1 (de)
SK (1) SK73898A3 (de)
SV (1) SV1997000008A (de)
TR (1) TR199800990T2 (de)
TW (1) TW546293B (de)
WO (1) WO1997020824A1 (de)
YU (1) YU21597A (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138027A (en) * 1995-12-08 2004-08-31 Agouron Pharma Intermediates for the preparation and preparation of metalloproteinase inhibitors
US6500948B1 (en) * 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
WO1998003164A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
JP3541043B2 (ja) 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー 置換環状アミンメタロプロテアーゼ阻害剤
DK0927168T3 (da) * 1996-08-28 2003-03-10 Procter & Gamble 1,3-diheterocykliske metalloproteaseinhibitorer
SK25199A3 (en) * 1996-08-28 2000-02-14 Procter & Gamble Heterocyclic metalloprotease inhibitors
NZ334254A (en) 1996-08-28 2000-11-24 Procter & Gamble Heterocyclic metalloprotease inhibitors
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
US6872742B2 (en) 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
WO1998016520A1 (en) * 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
EP0948489A1 (de) 1996-12-17 1999-10-13 Fujisawa Pharmaceutical Co., Ltd. Piperazin-verbindungen als mmp oder tnf inhibitoren
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
WO1998039329A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
CN1254337A (zh) 1997-03-04 2000-05-24 孟山都公司 N-羟基4-磺酰基丁酰胺化合物
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
NZ338082A (en) * 1997-04-01 2000-06-23 Agouron Pharma Metalloproteinase and Tumor Necrosis Factor-alpha convertase inhibitors, pharmaceutical compositions and their use in treating disease mediated by metalloproteinase activity.
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd 2−スルファモイル安息香酸誘導体
HUP0004595A3 (en) 1997-07-31 2001-12-28 Procter & Gamble Acyclic metalloprotease inhibitors
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のmmp媒介疾患の治療のためのmmp−13選択的阻害剤の使用
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
CN1279669A (zh) 1997-11-14 2001-01-10 G·D·瑟尔公司 芳族砜异羟肟酸金属蛋白酶抑制剂
AU2240299A (en) * 1998-01-27 1999-08-09 American Cyanamid Company 2,3,4,5-tetrahydro-1h-(1,4)-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
CN1195735C (zh) 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU3982599A (en) * 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
EP1087937A1 (de) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclische hydroxamsäuren als metalloproteinase-inhibitoren
ES2310636T3 (es) 1998-06-18 2009-01-16 F. Hoffmann-La Roche Ag Proceso para sulfuros de arilalquilo.
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
EP1104412B1 (de) * 1998-08-12 2005-06-15 Pfizer Products Inc. Tace inhibitoren
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
EP1117372A2 (de) * 1998-09-30 2001-07-25 The Procter & Gamble Company Verfahren zur haarausfallbehandlung unter verwendung von sulfoamiden
US6288261B1 (en) * 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
CA2356462A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
JP2002536373A (ja) 1999-02-08 2002-10-29 ジー・ディー・サール・アンド・カンパニー スルファメトヒドロキサム酸メタロプロテアーゼ阻害剤
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EP1165530A2 (de) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituierte metalloprotease-inhibitoren
IL145089A0 (en) 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
BR0109469A (pt) 2000-03-17 2003-04-29 Bristol Myers Squibb Co Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto
CN1481377A (zh) 2000-03-17 2004-03-10 ����˹�ж�-����˹˹����ҩƷ��˾ 作为基质金属蛋白酶和TNF-α的抑制剂的环β-氨基酸衍生物
EP1138680A1 (de) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituierte Sulfonylhydroxamsäuren mit MMP inhibierender Wirkung
AU4888401A (en) * 2000-04-07 2001-10-23 Samsung Electronics Co., Ltd. Sulfonamide derivative as a matrix metalloproteinase inhibitor
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
EP1355648A2 (de) 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company ZWEIFACH in 1,2-POSITION SUBSTITUIERTE CYCLISCHE HEMMER VON MATRIXMETALLOPROTEASEN UND TNF-$g(a)
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6825215B2 (en) 2001-01-11 2004-11-30 Bristol-Myers Squibb Pharma Company 1,1-disubstituted cyclic inhibitors of matrix metalloproteases and TNF-α
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
AU2002258507A1 (en) 2001-03-15 2002-10-03 Bristol-Myers Squibb Company Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
HUP0304069A2 (hu) 2001-05-11 2004-04-28 Pharmacia Corp. Aromás szulfon-hidroxamátok és proteázgátlókként való alkalmazásuk
WO2002096420A2 (en) * 2001-05-29 2002-12-05 Guilford Pharmaceuticals Inc. Method for treating nerve injury caused by surgery
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
WO2003037852A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2002356979A1 (en) * 2001-11-30 2003-06-17 Bristol-Myers Squibb Company Method of producing n-((2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl)-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
AU2003233154A1 (en) 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
EP2428509A1 (de) 2002-06-12 2012-03-14 Symphony Evolution, Inc. Humane Adam-10-Hemmer
EP1515951A1 (de) * 2002-06-25 2005-03-23 Pharmacia Corporation Derivate von arylsulfonylhydroxamsäuren und amiden sowie deren verwendung als protease inhibitoren
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1592389B1 (de) * 2003-02-14 2009-04-22 Laboratoires Serono SA Derivate von piperazine-2-carboxamide
WO2004073599A2 (en) * 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
MXPA05010055A (es) 2003-03-24 2005-11-23 Actimis Pharmaceuticals Inc Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
GT200500139A (es) 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
US8426415B2 (en) 2007-10-16 2013-04-23 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP2147684A1 (de) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Selektiv gegen Metallproteasen wirkende Diagnosemittel
WO2011081884A1 (en) 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
CN103998435A (zh) * 2011-10-04 2014-08-20 法国国家健康医疗研究院 新型细胞凋亡诱导化合物
CN113194954A (zh) 2018-10-04 2021-07-30 国家医疗保健研究所 用于治疗角皮病的egfr抑制剂
JP7484901B2 (ja) * 2019-04-26 2024-05-16 日産化学株式会社 アリールスルホン酸エステル化合物の製造方法
US20220227792A1 (en) * 2019-06-14 2022-07-21 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
EP0489577B1 (de) * 1990-12-03 1995-03-22 Celltech Limited Peptidylderivate
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
US5672583A (en) * 1992-11-25 1997-09-30 Merck & Co., Inc. Carboxy-peptidyl derivatives as antidegenerative active agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
HU222818B1 (hu) * 1993-08-05 2003-11-28 Syntex (U.S.A.) Inc. Mátrix metalloproteáz inhibitor hatású indolszármazékok, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
EP0740655B1 (de) * 1994-01-22 1999-10-20 British Biotech Pharmaceuticals Limited Metalloproteinaseinhibitoren
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
WO1995032944A1 (en) * 1994-05-28 1995-12-07 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
EP0757984B1 (de) * 1995-08-08 2002-10-30 Ono Pharmaceutical Co., Ltd. Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
PL186869B1 (pl) * 1995-11-13 2004-03-31 Hoechst Ag Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
IL138027A (en) * 1995-12-08 2004-08-31 Agouron Pharma Intermediates for the preparation and preparation of metalloproteinase inhibitors
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
PL327494A1 (en) * 1995-12-22 1998-12-21 Warner Lambert Co Aromatic keto-carboxylic acids and their derivatives as inhibitors of matrix metalloproteinases
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
JP3628335B2 (ja) * 1996-01-23 2005-03-09 塩野義製薬株式会社 スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤
EA199900139A1 (ru) * 1996-08-23 1999-08-26 Пфайзер, Инк. Производные арилсульфониламиногидроксамовой кислоты
JP3541043B2 (ja) * 1996-08-28 2004-07-07 ザ プロクター アンド ギャンブル カンパニー 置換環状アミンメタロプロテアーゼ阻害剤
SK25199A3 (en) * 1996-08-28 2000-02-14 Procter & Gamble Heterocyclic metalloprotease inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
NO982590D0 (no) 1998-06-05
HRP970031A2 (en) 1998-08-31
BG102510A (en) 1999-08-31
IL124559A0 (en) 1998-12-06
MY117290A (en) 2004-06-30
IL134816A (en) 2003-02-12
AP1368A (en) 2005-04-21
NZ325559A (en) 2000-01-28
SI0874830T1 (en) 2003-08-31
JP2000502330A (ja) 2000-02-29
ID17624A (id) 1998-01-15
AU1409197A (en) 1997-06-27
ATE283264T1 (de) 2004-12-15
AU725831C (en) 2002-10-17
DE69633947D1 (de) 2004-12-30
US6153757A (en) 2000-11-28
KR19990072009A (ko) 1999-09-27
NO311360B1 (no) 2001-11-19
EP0874830A1 (de) 1998-11-04
ATE234291T1 (de) 2003-03-15
PE69298A1 (es) 1998-11-13
IL138028A0 (en) 2001-10-31
BR9611929A (pt) 1999-05-18
CO4790150A1 (es) 1999-05-31
TW546293B (en) 2003-08-11
AP2001002270A0 (en) 2001-09-30
CN1207289C (zh) 2005-06-22
CN1542002A (zh) 2004-11-03
DE69633947T2 (de) 2005-12-01
CN1207734A (zh) 1999-02-10
DE69626684T2 (de) 2004-04-29
IL124559A (en) 2004-07-25
DE69626684D1 (de) 2003-04-17
EA199800541A1 (ru) 1998-12-24
OA10794A (en) 2001-07-05
YU21597A (en) 1999-11-22
CZ292942B6 (cs) 2004-01-14
BG64279B1 (bg) 2004-08-31
PL327275A1 (en) 1998-12-07
AU725831B2 (en) 2000-10-19
AP9801284A0 (en) 1998-09-30
TR199800990T2 (xx) 1998-07-21
SV1997000008A (es) 1999-02-15
GT199700015A (es) 1998-07-23
WO1997020824A1 (en) 1997-06-12
PA8431301A1 (es) 2000-05-24
IL143674A0 (en) 2002-04-21
AP1288A (en) 2004-07-21
ES2195034T3 (es) 2003-12-01
HUP9902092A2 (hu) 1999-09-28
MX9804457A (es) 1998-09-30
EP1095936A1 (de) 2001-05-02
EP0874830B1 (de) 2003-03-12
PT874830E (pt) 2003-06-30
NO982590L (no) 1998-08-05
CZ173398A3 (cs) 1998-11-11
IL138027A0 (en) 2001-10-31
SK73898A3 (en) 1999-01-11
EP1095936B1 (de) 2004-11-24
ES2233275T3 (es) 2005-06-16
IL134816A0 (en) 2001-05-20
CA2238306A1 (en) 1997-06-12
EA003294B1 (ru) 2003-04-24
GT199700015AA (es) 1998-07-23
GEP20012388B (en) 2001-03-25
DK0874830T3 (da) 2003-04-22
HUP9902092A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
AU725831C (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
US5753653A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
USH1992H1 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their pharmaceutical uses
US5985900A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
AU747280B2 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6500948B1 (en) Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
US8119673B2 (en) Compounds 148
EP4622713A1 (de) Verbindungen und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit der lpa-rezeptoraktivität
US20100173910A1 (en) Triaminopyrimidine cyclobutenedione derivatives used as phosphatase cdc25 inhibitors
EA012266B1 (ru) Сульфониламиноциклические соединения и их применение
MXPA99008995A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees